NEW ANTAGONIST COMPOUNDS
Field of the invention
The present invention is related to novel δ opioid receptor antagonists as well as to their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.
Background of the invention
Opiod antagonists have been indispensable as tools in opioid research. For example, the chief criterion for the classification of an agonist effect as being opioid receptor mediated is the ability of known opioid antagonists naloxone or naltrexone to reversibly antagonize this effect in a competitive fashion. The usefulness of naloxone and naltrexone for this purpose stems from the fact that they are universal opioid antagonists; that is, they are capable of antagonizing the agonist effects mediated by multiple opioid receptor types.
Since it is now firmly established that there are a minimum of three opioid receptor types (μ, K and δ), it has become increasingly evident that selective opioid antagonists are valuable pharmacological tools for identifying receptor types involved in the interaction with opioid agonists. One of the major advantages of selective opioid antagonists over selective agonists is their utility in probing the interaction of endogenous opioid peptides and new opioid agonists with opioid receptor types. Moreover, since it is sometimes not easy to distinguish among μ, K and δ opioid receptor mediated agonist effects if the pharmacological endpoints are identical (e.g. antinoάception or inhibition of a smooth muscle preparation by agonists), selective antagonists clearly have wider utility as tools than selective agonists.
The general utility of selective antagonists as pharmacological tools depends upon the correlation of in vitro and in vivo acitivity. This can be accomplished more easily with non-peptide ligands because they generally can penetrate the blood- brain barrier and therefore can be administered peripherally in vivo. Also, they are less subject to metabolism than are peptides.
In addition to their uses as pharmacological tools, selective, non-peptide opioid antagonists have been described as having potential clinical applications in the treatment of a variety of disorders where endogenous opioids play a modulatory role. These include for instance disorders of food intake, shock, constipation, mental disorders, CNS injury, alcoholism, and immune function (immune stimulation or suppression) (P.S. Portoghese et al., J. Med. Chem., Vol 34: 1757- 1762, 1991).
Non-peptide, competitive, δ-selective opioid antagonists have been found recently. The prototypes are: cyprodime for μ (H. Schmidhammer et al., J. Med. Chem., Vol. 32:418-421, 1989; H. Schmidhammer et al., J. Med. Chem., Vol. 33: 1200-1206, 1990), norbinaltorphimine for (P. S. Portoghese et al., J. Med. Chem., Vol. 30:238-239, 1987), and naltrindole for δ opioid receptors (P.S. Portoghese et al., J. Med. Chem., Vol. 31:281-282, 1988).
These compounds (cyprodime, norbinaltorphinine and naltrindole) are being used as pharmacological tools. They have been tritium labelled and can be used as receptor selective ligands in opioid receptor binding studies to sort out the affinities of new ligands to different receptors and to determine whether a compound is selective to a special receptor.
An object of the present invention was to find new, highly selective δ opioid receptor antagonists with high potency. Another object was to find highly selective δ opioid receptor antagonists with high immunosuppressive potency. The high selectivity for δ opioid receptors would repress adverse side effects
caused by the interaction with other receptors. Still another object was to find compounds which have a brain-cell protecting effect. The problem with the δ opiod receptor antagonists known from the prior art is that they are not highly selective.
Prior art
Certain opioid agonists represented by morphine, which act on μ receptors, are known to exhibit immunosuppressive effects. The agonist enkephalin, which acts on δ opioid receptors, exhibit immunostimulating effects (Plotnikoff, Enkephalins and Endorphins, Stress and Immune System, Plenum Press, 1986). Although a number of reports have been issued concerning the immunosuppressive effects of agonists of μ receptors, it is difficult to develop an immunosuppressive agent by employing an agonist of μ receptors, since such agonists show critical side effects such as addiction, respiratory depression, constipation etc.
Recently it has been reported that δ-selective opioid antagonists have immunosuppressive effects. See EP 456 833, EP 485 636 and EP 614 898.
Outline of the invention
The present invention provides novel compounds of the formula (I)
wherein
R- represents C.-C-
g alkenyl; C
4-C
10 cycloalkylalkyl wherein the cycloalkyl is C
3-C
6
cycloalkyl and the alkyl is C--C4 alkyl; C4-C10 cykloalkenylalkyl wherein the
cycloalkenyl is C3-C6 cykloalkenyl and the alkyl is C--C4 alkyl; C7-C16 arylalkyl
wherein the aryl is C6-C10 aryl and the alkyl is C--C6 alkyl; C8-C16 arylalkenyl
wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl;
R-, represents hydrogen, hydroxy, C--C6 alkoxy; C.-C6 alkenyloxy; C7-C16
arylalkyloxy wherein the aryl is C6-C10 aryl and the alkyloxy is C--C6 alkyloxy; C7-
C16 arylalkenyloxy wherein the aryl is C6-C10 aryl and the alkenyloxy is C.-C6
alkenyloxy; C--C6 alkanoyloxy; C7-C16 arylalkanoyloxy wherein the aryl is C6-C10
aryl and the alkylaroyloxy is Cα-C6 alkylaroyloxy;
R3 represents hydrogen, C--C6 alkyl; C--C6 alkenyl; C7-C16 arylalkyl wherein the
aryl is C6-C10 aryl and the alkyl is Cα-C6 alkyl; C7-C16 arylalkenyl wherein the aryl
is C6-Cl0 aryl and the alkenyl is C--C6 alkenyl; hydroxy(Cj-C6)alkyl; alkoxyalkyl
wherein the alkoxy is C--C6 alkoxy and the alkyl is C--C6 alkyl; C02H; C02(C.-C6 alkyl);
R4 is hydrogen, hydroxy; C--C6 alkoxy; C7-C16 arylalkyloxy wherein the aryl is C6-
C10 aryl and the alkyloxy is C--C6 alkyloxy; C--C6 alkenyloxy; C--C6 alkanoyloxy;
C-,-C16 arylalkanoyloxy wherein the aryl is C6-C10 aryl and the alkanoyloxy is C.-
C6 alkanoyloxy; C2-C10 alkyloxyalkoxy wherein alkyloxy is C--C4 alkyloxy and
alkoxy is C--C6 alkoxy;
R5 and R6 each independently represent hydrogen; OH; C--C6 alkoxy; C--C6 alkyl;
hydroxyalkyl wherein the alkyl is C--C6 alkyl; halo; nitro; cyano; thiocyanato;
trifluoromethyl; C02H; C02(C--C6 alkyl); CONH2; CONH(C1-C6 alkyl); CON(Cr
C6 alkyl)2; amino; C--C6 monoalkyl amino; C--C6 dialkyl amino, C5-C6
cycloalkylamino; SH; S03H; S03(C--C6 alkyl); S02(C--C6 alkyl); S02NH2;
S02NH(C--C6 alkyl); S02NH (C7-C-6 arylalkyl); SO(C1-C6 alkyl); or R5 and R6 together form a phenyl ring which may be unsubstituted or substituted by halo, nitro, cyano, thiocyanato; C--C6 alkyl; trifluoromethyl; C--C6 alkoxy, C02H,
CO(C--C6 alkyl), amino, C--C6 monoalkylamino, C--C6 dialkylamino, SH; S03H;
S03(C.-C6 alkyl), S02(C C6 alkyl), SO(C--C6 alkyl), and
X represents oxygen; sulfur; CH=CH or NR„ wherein R, is H, C--C6 alkyl, C--C6
alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C--C6
alkyl, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C.-C6
alkenyl; C--C6 alkanoyl,
with the proviso that when Rj is hydroxy Rg cannot be hydrogen, except when R4
is hydrogen, OCH2OCH3, OCH2OC2H5 or OCCPh)^
and pharmacologically acceptable salts thereof.
By aryl the following definitions are intended throughout the hole patent application.
Aryl may be unsubstituted or mono-, di- or trisubstituted independently with hydroxy, halo, nitro, cyano, thiocyanato, trifluoromethyl, C.-C3 alkyl, C--C3
alkoxy, C02H, C02 (C--C3)alkyl, CONH2, CONH(Ct-C3 alkyl), CON(C--C3 alkyl)2,
CO(C--C3 alkyl), amino, (C--C3 monoalkyl)amino, (C.-C3 dialkyl)amino, C5-C6
cycloalkylamino, (C--C3 alkanoyDamino, SH, S03H, S03 (C--C3 alkyl), S02 (C C3
alkyl), SO(C--C3 alkyl), C--C3 alkylthio or C--C3 alkanoylthio.
In a preferred embodiment
R- is selected from allyl, cinnamyl, cyclopropylmethyl or cyclobutylmethyl;
Rj is selected from methoxy, ethoxy, n-propyloxy, benzyloxy, benzyloxy
substituted in the aromatic ring with F, Cl, N02, CN, CF3, CH3 or OCH3; allyloxy, cinnamyloxy or 3-phenylpropyloxy;
Rg is selected from hydrogen, methyl, ethyl, benzyl or allyl;
R4 is selected from hydroxy, methoxy, methoxymethoxy or acetyloxy;
R5 and R6 are each and independently selected from hydrogen, nitro, cyano,
chloro, fluoro, bromo, trifluoromethyl; C02H; C02 CH3, CONH2; CONH CH3,
CH3, SH; S02NH2; N(CH3)2, S02 CH3; and
X is selected from O, NH, N CH3, N-benzyl, N-allyl.
In an especially preferred embodiment R- is allyl or cyclopropylmethyl;
Rj is selected from methoxy, ethoxy, n-propyloxy, benzyloxy substituted in the aromatic ring with chlorine;
Rg is selected from hydrogen or CH-;
R4 is hydroxy
R5 and R6 are each independently selected from hydrogen, C02H, CONH2,
S02NH2 or S02CH3; and X is selected from O or NH.
The best mode known at present is to use the compounds of Examples 1, 6, 8, 18, 24, 41 and 42.
The novel compounds according to the invention are useful as immunsuppressive agents and/or as analgesics, and also after CNS-injuries by exerting a brain-cell protecting effect.
Earlier studies (cf. page 3) accomplished with δ-selective opioid antagonists have shown that this class of compounds exhibits immunosuppressive effects. Thus, the compounds of formula (I) of the present invention may be used for suppressing the rejection of transplants after organ transplantations and may be used in the treatment of rheumatic diseases, e.g. rheumatoid arthritis and/or as analgesics.
Pharmaceutically and pharmacologically acceptable salts of the compounds of formula I are also comprised in the invention. Suitable salts are inorganic salts such as HCl salt, HBr salt, sulfuric acid salt, phosphoric acid salt. Organic acid salts such as methanesulfonic acid salt, salicylic acid salt, fumaric acid salt, maleic acid salt, succinic acid salt, aspartic acid salt, citric acid salt, oxalic acid salt, orotic acid salt, although the salts are not restricted thereto, can also be used according to the invention.
Preparation
The compounds represented by formula (I) may be obtained by the following methods:
Thebaine of the formula
is being treated with dialkylsulfates, fluorosulfonic acid alkyl esters, alkylsulfonic acid alkyl esters, arylsulfonic acid alkylesters, alkyl halides, aralkyl halides, alkylsulfonic acid aralkyl esters, arylsulfonic acid aralkyl, arylalkenyl halides, chloroformates, in solvents such as tetrahydrofurane or diethyl ether using a strong base such as n-butyl lithium, lithium diethyl amide or lithium diisopropyl amide at low temperatures (-20 to -80 °C) (s. Boden et al., J.org.Chem.,Vol.47: 1347-1349, 1982; Schmidhammer et al, Helv.Chim.Acta, Vol.71:642-647, 1988), giving compounds of the formula II
R is C1-C6 alkyl; C--C6 alkenyl; C7-C16 aralkyl wherein the aryl is C6-C10 aryl and
the alkyl is C--C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the
alkenyl is C--C6 alkenyl; alkoxyalkyl wherein the alkoxy is C.-C6 alkoxy and the
alkyl is C.-C6 alkyl; C02 (C.-C6 alkyl); The substituted thebaine derivatives
(formula (II)) or thebaine are converted into the corresponding 14- hydroxycodeinones according to formula III
R is as defined above or being hydrogen, by reaction with performic acid (s. Schmidhammer et al., Helv.Chim.Acta, Vol. 71:1801-1804, 1988) or m-chloroperbenzoic acid at a temperature between 0 and
60 °C. The preferred procedure is the reaction with performic acid at 0-10 °C (H.
Schmidhammer et al., Helv.Chim.Acta, Vol. 71:1801-1804, 1988). These 14- hydroxycodeinones being treated with dialkyl sulfates, alkyl halides, alkenyl halides, aralkyl halides, arylalkenyl halides, chloroformates, in solvents such as N.N-dimethyl formamide or tetrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide giving compounds of formula (IV),
wherein
R, is C--C
6 alkyl, C--C
6 alkenyl, C
7-C
16 arylalkyl wherein the aryl is C
6-C
l0 aryl
and the alkyl is C,-C6 alkyl, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and
the alkenyl is C--C6 alkenyl, C--C6 alkanoyl, C7-C20 arylalkanoyl wherein the aryl
is C6-C14 aryl and the alkyl is C--C6 alkyl, C7-C20 arylalkenoyl wherein the aryl is
C6-C]4 aryl and the alkyl is C--C6 alkenoyl;
R-, is hydrogen; C--C6 alkyl; C--C6 alkenyl C7-C]6 arylalkyl wherein the aryl is C6-
C10 aryl and the alkyl is C.-C6 alkyl; C7-C]6 arylalkenyl wherein the aryl is C6-C-0
aryl and the alkenyl is C--C6 alkenyl; alkoxyalkyl wherein the alkoxy is C--C6
alkoxy and the alkyl is C--C6 alkyl; C02(C.-C6 alkyl);
which in turn are reduced by catalytic hydrogenation using a catlayst such as palladium on charcoal and solvents such as methanol, ethanol or glacial acetic acid to give compounds of formula (V)
R. is C--C6 alkyl, C7-C]6 arylalkyl wherein the aryl is C6-C]0 aryl and the alkyl is
C1-C6 alkyl, C.-C6 alkanoyl, C7-C16 arylalkanoyl wherein the aryl is C6-C10 aryl and
the alkanoyl is C-^-C8 alkanoyl; and
R-, is hydrogen; C--C6 alkyl, C,-C6 alkenyl C7-C16 arylalkyl wherein the aryl C6-C10
aryl and the alkyl is C--C6 alkyl; C7-C]6 arylalkenyl wherein the aryl is C6-C10 aryl
and alkenyl is C.-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C--C6 alkyl;
C02(C--C6 alkyl);
Thereafter N-demethylation can be carried out using chloroformates or cyanogen bromide to give intermediates of formula (VI)
R. and Rj are as defined above in formula (IV); and
R3 is C02CHC1CH3, C02CH=CH2, C02CH2CC13, C02CH2CH3, C02Ph, CN or the like.
The intermediate carbamates of formula (VI) can be cleaved by refluxing in alcohols (in the case of 1-chloroethyl carbamates), by addition of hydrogen halides or halogen and subsequent refluxing in alcohols (in the case of vinyl carbamates), or by reductive cleavage using zinc in glacial acetic acid or methanol (in the case of 2,2,2-trichloroethyl carbamates). Other carbonates may be cleaved using aqueous acid, alkali or hydrazine. The intermediate cyanamides of formula (VI) can be cleaved by acid hydrolysis. Alkylation of the corresponding N-nor derivatives of formula (VII)
wherein
R- and Rj are as defined above in formula (V), can be accomplished with alkenyl halides, cycloalkylalkyl halides, cycloalkenylalkyl halides, aralkyl halides, arylalkenyl halides, in solvents such as dichloromethane, chloroform, or N,N- dimethyl formamide in the presence of a base such as sodium hydrogen carbonate or potassium carbonate to yield derivatives of formula (VIII)
R. and Rj are as defined above in formula (V); and
Rj represents C--C6 alkenyl; C7-C]6 arylalkyl wherein the aryl is C6-C10 aryl and
the alkyl is C--C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the
alkenyl is C--C6 alkenyl; C4-C10 cycloalkylalkyl wherein the cycloalkyl is C3-C6
cycloalkyl and the alkyl is C.-C4 alkyl; C4-C10 cycloalkylalkenyl wherein the
cycloalkenyl is C3-C6 cycloalkenyl and the alkyl is C--C4 alkyl;
Ether cleavage can be carried out using boron tribromide (in a solvent such as dichloromethane or chloroform at about 0 °C), 48 % hydrobromic acid (reflux), or other well known reagents for ether cleavage. The resulting phenols of formula (IX)
R-, Rj and Rj are as defined above, are being alkylated using alkyl halides, alkyl sulfates, sulfonic acid esters, aralkyl halides, arylalkenyl halides or acylated using carbonic acid chlorides, or carbonic acid esters to yield compounds of formula (X)
R-, Rj and Rg are as defined above; and
R4 is hydrogen, C--C6 alkyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and
the alkyl is C.-C6 alkyl, C--C6 alkenyl, C7-C16 arylalkenyl wherein the aryl is C6-C10
aryl and the alkenyl is C1-C6 alkenyl; C--C6 alkanoyl, C7-C16 arylalkanoyl wherein
the aryl is C6-C10 aryl and the alkanoyl is C--C6 alkanoyl, C2-C10 alkyloxyalkyl
wherein alkyloxy is C--C4 alkyloxy and alkyl is C--C6 alkyl,
Compounds of the formula (I) wherein F^ is hydroxy may be obtained from compounds of formula (III) wherein R is defined as above. These compounds may be reduced by catalytic hydrogenation using a catalyst such as palladium on charcoal and solvents such as methanol, ethanol, or glacial acetic acid to give compounds of the formula (V) wherein R- is hydrogen and Rj is defined for R in formula (II).
The following reaction sequence and procedures leading to compounds of formulas (VI), (VII), (VIII), (IX) and (X) wherein the substituent in position 14 is hydroxy and the other substitutents are defined as above, is analogous to the reaction sequence and procedures described above. Further conversion to compounds of the formula (I) wherein 1^ is hydroxy is described below.
Compounds of the formula (I) wherein R^ is hydrogen may be obtained from compounds of the formula (II) wherein R is as defined above or hydrogen. Catalytic hydrogenation followed by acid hydrolysis (s. Boden et al, J. Org. Chem. Vol. 47:1347-1349, 1982) may provide compounds of formula (XI)
(XIa): R=H (dihydrocodeinone)
wherein R is as defined above in formula (II) or hydrogen.
Compounds of the formula (XI) and (XIa) (Mannich and Lόwenheim, Arch.Pharm.Vol. 258:295, 1920) can be converted into compounds of formulas (V), (VI), (VII), (VIII), (IX), and (X) wherein the substituent in position 14 is hydrogen
and R2 and R3 are as defined above, similarly as outlined above. Further
conversion into compounds of the formula (I) wherein Rj is hydrogen is described below.
Compounds of the formula (I) wherein R4 is hydrogen may be prepared from
compounds of the formula (IX) by alkylation with 5-chloro-l-phenyl- H-tetrazole to give the corresponding phenyltetrazolyl ethers of the formula XII)
wherein R-, 1^ and Rg are as defined above and R- also can be CH3, and T is phenyl tetrazolyl.
Catalytic hydrogenation may afford (H. Schmidhammer et al., J. Med. Chem. Vol. 27:1575-1579, 1984) compounds of the formula (XIII)
wherein R Rj and Rg are as defined above and R- also can be CH^
In the case R. is CH3, the N-methyl group has to be removed and the nitrogen alkylated as described above.
Alternatively, compounds of formula (I) wherein R- represents allyl or
cyclopropylmethyl and Rg represents H can be obtained by a shorter route starting either from naloxone (XlVa) or naltrexone (XlVa).
(XlVa): Naloxone - R is allyl (XlVb): Naltrexone - R is cyclopropylmethyl.
The 3-hydroxy group of compounds of formula (XIV) is being protected by alkylation with benzyl bromide, methoxymethyl bromide, ethoxymethyl bromide or trityl chloride (triphenylmethyl chloride) in a solvent such as N,N-dimethyl formamide or dichloromethane in the presence of a base to yield compounds of formula (XV)
R is allyl or cyclopropylmethyl and Y = CH2Ph, CH2OCH3, CH2OC2H5 or C(Ph)3.
These compounds are alkylated, alkenylated, cycloalkylalkylated, arylalkylated or arylalkenylated with dialkyl sulfates, alkyl halides, alkenyl halides, arylalkyl halides or arylalkenyl halides in solvents such as N,N-dimethyl formamide or tetrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide. The resulting 6-0,14-0-dialkylated compounds of formula (XVI)
R- is allyl or cyclopropylmethyl; and
Rj, is C--C6 alkyl, C--C6 alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl
and the alkyl is C--C6 alkoxy, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl
and alkenyl is C--C6 alkenyl; and Y as defined above;
can be hydrolized with diluted acids like hydrochloric acid or sulfuric acid to afford compounds or formula (XVII)
Rj is allyl or cyclopropylmehtyl; and
R2 is as defined above (formula XVI).
In the case R2 is alkenyl or arylalkenyl the double bond may be reduced by catalytic hydrogenation to afford the corresponding saturated derivatives. Further conversion into compounds of formula (I) is described below.
Alternatively, compounds of formula (I) wherein R- represents allyl or
cyclopropylmethyl and Rg represents H can be prepared also via the following route: The carbonyl group in position 6 of naloxone (XVa) and naltrexone (XVb), respectively, is being protected by reaction with ethylene glycol in the presence of an acid (e.g. methanesulfonic acid) at temperatures between 20 and 200 °C to give ketals of formula (XVIII)
wherein R is allyl or cyclopropylmethyl.
The 3-hydroxy group of these ketals is being protected by alkylation with benzyl bromide, methoxymethyl bromide, ethoxymethyl bromide or trityl chloride in a solvent such as N,N-dimethyl formamide or dichloromethane in the presence of a base to yield compounds of formula (XIX)
wherein R is allyl or cyclopropylmethyl and Y is as defined above.
These compounds are alkylated, alkenylated, arylalkylated or arylalkenylated with dialkyl suflates, alkyl halides, alkenyl halides, arylalkyl halides or arylalkenyl halides in solvents such as N,N-dimethyl formamide or tetrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide. The resulting compounds of formula (XX)
wherein R- is allyl or cyclopropylmethyl, Rj is as defined above (formula (XVI)) and Y is as defined above
can be hydrolized in diluted acids like hydrochloride acid or sulfuric acid (a typical mixture for hydrolysis is: concentrated HCl: MeOH: H203/6/1 v/v/v) to
afford compounds of formula (XVII). Compounds of formula (I) wherein R-
represents allyl or cyclopropyl-ethyl, R3 represents H, and X represents NH or O can be prepared from compounds of formula (XVII) as described below.
Compounds of the formula (I) wherein Rg is as defined above and X represents NH are obtained by reaction of compounds of formula (Vffi), (X) or (XIII) with phenylhydrazine or substituted phenylhydrazine in solvents such as methanol, ethanol or glacial acetic acid in the presence of methanesulfonic acid, HCl or HBr.
Phenylhydrazine substituted at the aromatic ring with hydroxy, halogen, C.-C6
alkyl, C--C6 alkoxy, amino, nitro, cyano, thiocyanato, trifluoromethyl, C02H, C02
(C--C6) alkyl, CONH2, CONH (C.-C6 alkyl), CON (C.-C6 alkyl)2, S02NH2, S02 (C
C6) alkyl or the like may be employed. The reaction may be carried out at a temperature between 20 and 160 °C, preferably between 20 and 80 °C.
Compounds of formula (I) wherein Rg is as defined above and X represents O are obtained by reaction of compounds of formula (VIII), (IX), (X) or (XIII) with O- phenylhydroxyl amine or substituted (at the aromatic ring) O-phenylhydroxyl- amine in solvents such as methanol ethanol, or glacial acetic acid in the presence of methanesulfonic acid, HCl or HBr. O-phenylhydroxylamine substituted at the aromatic ring with hydroxy, halogen, C--C6 alkyl, C--C6 alkoxy, amino, nitro,
cyano, thiocyanato, trifluoromethyl, C02H, C02 (C--C6) alkyl, CONH2, CONH
(C C6 alkyl), CON (C C6 alkyl)2, S02NH2, S02 (C--C6) alkyl or the like may be employed.
The invention will now be described in more detail by the following examples which are not to be construed as limiting the invention.
Examples
Example 1
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-ethoxy-3- hydroxy -5-methyl-6,7-2',3'-indolomorphinan hydrochloride (compound 1).
A mixture of 14-0-ethyl-5-methylnaltτexone (H. Schmidhammer et al, Helv. Chim. Acta, Vol. 76: 476-480, 1993) (580 mg, 1.51 mmol), phenylhydrazine hydrochloride (394 mg, 2.72 mmol), and 7 ml of glacial acetic acid was refluxed for 23 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH4OH and extracted with CH2C12 (3x30 ml). The combined organic layers
were washed with H20 (3x80 ml), dried over Na2S04 and evaporated. The remaining residue (615 mg brownish foam) was dissolved in little MeOH and Et20/HCl was added. Thus, 550 mg (95%) of the compound 1 were isolated. For analysis a small amount was recrystallized from MeOH. m.p. > 260°C (dec.) IR
(KBr): 3200 CNH, NH, OH)cm . CI-MS:m/z 457 (M' +1). 7H-NMR ((d6)DMSO): δ
11.34, 9.21. and 8.55 (3 s, *NH, NH, OH), 7.32 (m, 2 arom. H), 7.08 (t, J = 8.1 Hz, 1 arom. H), 6.94 (t, J = 8.1 Hz, 1 arom. H), 6.62 (d, J = 8.1 Hz, 1 arom. H); 6.55 (d. J = 8.1 Hz, 1 arom. H), 1.86 (s, CH3-C(5)), 1.01 (t, J = 6.8 Hz, 3H, CH3CH20). Analysis
calculated for C29 H32N203.HC1.H20 (511.06): C 68.16, H 6.90, N 5.48, Cl 6.94; found: C 67.87, H 6.88, N 5.30, Cl 7.28.
Example 2
Synthesis of 17-Allyl-6,7-dihydro-4,5α-epoxy-14-ethoxy-3-hydroxy-5-methyl-6,7- 2',3'-indolomorphinan hydrochloride (compound 2).
A mixture of 14-0-ethyl-5-methylnaloxone (H. Schmidhammer et al., Helv. Chim. Acta Vol. 76:476-480, 1993) (1.2g, 2.66 mmol), phenylhydrazine hydrochloride (577 mg, 3.99 mmol), and 15 ml of glacial acetic acid was refluxed for 24 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH4OH and
extracted with CH2C12 (3x80 ml), 1x30 ml). The combined organic layers were
washed with H20 (3x80 ml, 1x30 ml), dried over Na2S04 and evaporated. The residue (1.3 g yellow-brown foam) was purified with column chromatography
(alumina basic grade IV, elution with CH
2C1
2). The corresponding fractions were combined and evaporated to give a colorless oil which was converted into the hydrochloride salt in the usual way and crystallized from MeOH/diethyl ether to yield 200 mg (17%) of the title compound 2. M.p. 168-170°C. IR
(CD
3OD): δ 7.39 (dd, J=7.8, 7.8 HZ, 2 arom. H), 7.14 (t, J=7.8 hz, 1 arom.H), 7.01
(t=7.8 HZ, 1 arom. H), 6.67 (s,2 arom. H), 6.02 (m, 1 olef. H), 5.72 (m, 2 olef. H), 1.99 (s, CH3-C(5)), 1.09 (t, J=6.8 Hz, CH3). Analysis calculated for C28H30N2O3.
HCl. 1.5 H20 (506.05): C 66.46, H 6.77 N 5.54, Cl 7.01; found: C 66.55, 6.68, N 5.39, Cl 6.98.
Eaxmple 3
Synthesis of 6,7-Dehydro-4,5α-epoxy-14-ethoxy-3-hydroxy-5-methyl-17-(2- phenyl)ethyl-6,7-2',3'-indolomorphinan hydrochloride (compound 5).
A mixture of 4,5α-epoxy-14-ethoxy-3-methoxy-5-methylmorphinan-6-one hydrochloride (H. Schmidhammer et al., Helv. Chim. Acta Vol. 76, 476-480,1993) (3.0 g, 7.88 mmol), potassium carbonate (3.9 g, 28.2 mmol), 2-phenylethyl bromide (1.41 ml, 10.4 mmol), and of 20 ml anhydrous N,N-dimethyl formamide was stirred at 80°C (bath temperature) for 2h. After cooling and addition of 130 ml of
H20, the mixture was extracted with diethyl ether (3x60 ml). The combined
organic layers were washed with H20 (3x70 ml), dried over Na2S04 and evaporated. The residue (3.6 yellow oil) was crystallized from MeOH to afford 2.1 g (70%) of 4,5α-epoxy-14-ethoxy-3-methoxy-5-methyl-17-(2- phenyl)ethylmorphinan-6-one (compound 3). M.p. 86-89°C. IR (KBr): 1725 (CO) cm"1. CI-MS: m/z 448 (M++l). ^-NMR (CDC13): δ 7.21 (m, 5 arom. H), 6.64
(d,J=8.2 Hz, 1 arom. H, 6.54 (d, J=8.2 Hz, 1 arom. H.), 3.85 (s, OCH3), 1.60 (s, CH3-
C(5)), 1.12 (t, J=6.8 Hz, CH3). Analysis calculated for C^H^NO. (447.55): C 75.14,
H 7.43, N 3.13; found: C 75.04, H 7.69, N 3.26.
A solution of the compound 3 (1.5 g, 3.35 mmol) in 5 ml of 48% HBr was refluxed for 30 min and then evaporated. The residue was dissolved in MeOH and again evaporated (this procedure was repeated twice) to give a grey crystall ne residue (1.7 g) which was treated with hot MeOH to yield 950 mg (63%) of the compound 4. M.p.>270°C. IR (KBr): 1720 (CO) cm'\ CI-MS: m/z 434 (M*+l). !H-NMR
(DMSO-d6): δ 9.38 and 8.48 (2 s, *NH, OH), 7.33 (m,5 arom. H), 6.68 (d, J=8.2 Hz, 1
arom. H), 6.64 (d, J=8.2 Hz, 1 arom. H), 1.51 (s, CH3-C(5)), 1.34 (t, J=6.8 Hz, CH3).
Analysis calculated for C27H3]N04. HBr (514.45):C 63.04, H 6.27, N 2.72, Br 15.53; found: C 63.15, H 6.48, N 2.61, Br 15.37.
A mixture of the compound 4 (700 mg, 1.61 mmol), phenylhydrazine hydrochloride (513 mg), 3.54 mmol), and 15 ml of glacial acetic acid was refluxed for 6 h. The reaction mixture was poured on ice, alkalized with cone. NH4OH and
extracted with CH2C12 (3x80 ml, 1x30 ml). The combined organic layers were
washed with H20 (3x80 ml), dried over Na2S04 and evaporated. The residue (600 mg slightly brown foam) was converted into the hydrochloride salt in the usual way and crystallized from MeOH/diethyl ether to yield 360 mg (51 %) of the title compound 5 as slightly pink crystals. M.p.>225°C. IR (KBr):3400 and 3200 CNH,
NH,OH). CI-MS:m/z 507 (M'+l). H-NMR (DMSO-d6):δ 11.34, 9.19 and 8.97 CNH,
NH, OH), 7.34 (m, 7 arom. H), 7.08 (t, J=7.9 Hz, 1 arom.), 6.94 (t, J=7,9 Hz, 1 arom. H), 6.62 (d, J=8.4 Hz, 1 arom. H), 6.57 (d, J=8.4 Hz, 1 arom. H), 1.87 (s, CH3- C(5)),0.96 (t, J=6.9 Hz, CH3). Analysis calculated for C^H^N- ,. HC1.2 H20
(579.14): C 68.44, H 6.79, N 4.84, Cl 6.12; found: C 68.81, H 6.55, N 4.72, Cl 6.40.
Example 4
Synthesis of 17-Allyl-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-methoxy-5-methyl- 6,7-2'^'-indolomorphinan hydrochloride (compound 6).
A mixture of 14-0-methyl-5-methylnaloxone (H. Schmidhammer et al., Helv. Chim. Acta Vol. 77:1585-1589, 1994) (1.0 g, 2.8 mmol), phenylhydrazine hydrochloride (728 mg, 5.04 mmol), and 15 ml of glacial acetic acid was refluxed for 24 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH4OH and extracted with CK,^ (3x80 ml, 1x30 ml). The combined
organic layers were washed with F-^O (3x80 ml), dried over Na2S04 and
evaporated. The residue (1.1 g brownish foam) was converted in the usual way into the hydrochloride salt and crystallized from acetone to yield 190 mg (19%) of the tide compound 6 as slightly brown crystals. M.p. >280°C. IR (KBr): 3200 CNH,
NH,OH), ]H-NMR: δ 7.32 (dd, J=7.9, 7.9 Hz, 2 arom. H), 7.06 (t, J=7.9 Hz, 1 arom. H), 6.93 (t, =7.9 Hz, 1 arom. H), 6,63 (d, J=8.2 Hz, 1 arom. H), 6.55 (d, J=8.2 Hz, 1 arom. H), 6.02 (m, lolef.H), 5.63 (m, 1 olef. H), 3.15 (s, OCH3), 2.07 (s, CH3-C(5)).
Analysis calculated for C27H2gN203. HCl. 1.7 H20. 0.9 MeOH (524.44): C64.41, H 7.09, N 5.22; found: C 64.44, H 6.87, N 4.94.
Example 5
Synthesis of 6,7-Dehydro-4,5α-epoxy-3-hydroxy-14-methoxy-5-methyl-17-(2- phenyl)ethyl-6,7-2',3'-indolomorphinan Hydrochloride (compound 9).
A mixture of 4,5α-epoxy-3,14-diιnethoxy-5-memylmorphinan-6-one hydrochloride (H. Schmidhammer et al., Helv. Chim. Acta Vol. 77:1585-1589, 1994) (2.24 g, 6.12 mmol), potassium carbonate (3.0 g, 21.9 mmol), 2-phenylethyl bromide (1.05 ml, 7.74 mmol), and 15 ml of anhydrous NJST-dimethyl formamide was stirred at 80°C (bath temperature) for 2 h. After cooling and addition of 110 ml of TrL D, the mixture was extracted with diethyl ether (3x60 ml). The combined
organic layers were washed with H20 (3x70 ml), dried over Na2S04 and evaporated. The residue (2.9 yellow oil) was converted into the hydrobromide salt in the usual way and crystallized from MeOH to give 1.4 g (63%) of 4,5α-epoxy- 3,14-dimethoxy-5-methyl-17-(2-phenyl)ethylmorphinan-6-one hydrobromide (compound 7) as colorless crystals. A small portion of this material was recrystallized from MeOH for analyses. M.p. 94-96°C. IR (KBr): 3400 CNH), 1720
(CO) cm'1. CI-MS: m/z 434 (M*+l). ^-NMR (DMSO-d6) δ 10.15 (s, *NH), 7.30 (m,
5 arom. H), 6.74 (d, J=8.2 Hz, 1 arom. H), 6.68 (d, J=8.2 Hz, 1 arom.), 3.87 (s,
OCH3-C(3)), 3.58 (s, OCH3-C(14)), 1.60 (s, CH3-C(5)). Analysis calculated for
C27H31N04. HBr (514.44): C 63.04, H 6.27, N 2.72; found: C 63.18, H 6.60, N 2.39.
A solution of the compound 7 (1.4 g, 3.32 mmol) in 5 ml of 48% HBr was refluxed for 30 min and then evaporated. The residue was dissolved in MeOH and again evaporated (this operation was repeated once) to afford a brownish crystalline residue (1.8 g) which was treated with hot MeOH to yield 590 mg (42%) of the compound 8.HBr. A small portion was recrystallized for analyses. M.p.>316°C. IR
(KBr):3400 CNH, OH), 1722 (CO)cm'1. CI-MS: m/z 420 (M*+l). ^-NMR (DMSO-
d6) δ 8.95 and 8.45 (2s, "NH,OH), 6.90 (m, 5 arom. H), 6.23 (dd, J=8.2, 8.2 Hz, 2
arom. H), 2.97 s, OCH3), 1.08 (s, CH3-C(5)). Analysis calculated for C26H29N04.
HBr. 0.2 MeoH (506.85): C 62.09, H 6.13, N 2.76, Br 16.77; found: C 61.79, H 6.18, N 2.63, Br 16.12.
A mixture of the compound 8. HBr (468 mg, 0.93 mmol), phenylhyrazine hydrochloride (343 mg, 2.36 mmol), and 15 ml of glacial acetic was refluxed for 7 h. After cooling, the reaction mixture was poured on ice, alkalized with con.
NH4OH and extracted with CH2C12 (3x70 ml, 1x30 ml). The combined organic
layers were washed with H20 (3x80 ml), dried over Na2S04 and evaporated. The residue (410 mg slightly brown foam) was converted into the hydrochloride salt in the usual way and crystallized from MeOH/diethyl ether to give 390 mg (83%) of the title compound 9 as slightly pink crystals. An analytic sample was obtained by recrystallization of a small portion of this material from MeOH/diethyl ether.
M.p.257-260°C (dec). IR (KBr): 3460 CNH, NH, OH) cm'1. CI-MS: m/z 493
(M*+l). H-NMR (DMSO-d6) δ 11.30, 9.20 and 9.05 (3 S, *NH, NH, OH), 7.25 (m, 7 arom. H), 7.10 (t, J=8.2 Hz, 1 arom. H), 6.96 (t, J=8.2 Hz, 1 arom. H), 6.59 (dd, J= 8.2, 8.2 Hz, 2 arom. H), 3.32 (s, OCH3), 1.87 (s, CH3-C(5)). Analysis calculated for
C32H32N203. HCl. 3.7 MeOH (647.63): C 66.21, H 7.44, N 4.33; found: C 66.04, H 7.13, N 4.60.
Example 6
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5c--epoxy-3-hydroxy-14- methoxy-5-methyl-6,7-2',3'indolomorphinan Hydrochloride (compound 10).
A mixture of 14-0-methyl-5-methylnaltrexone (H.Schmidhammer et al., Helv. Chim. Acta Vol. 77: 1585-1589, 1994) (620 mg, 1.68 mmol), phenylhydrazine hydrochloride (365 mg, 2.52 mmol), and 7 ml of glacial acetic acid was refluxed for 17.5 h. After cooling, the reaction mixture was poured on ice, alkalized with
NH4OH and extracted with CH2C12 (3x70 ml, 1x20 ml). The combined organic
layers were washed with H20 (3x80 ml), dried over Na2S04 and evaporated. The residue (1.11 g brown foam) was purified by column chromatography (silica gel
230-400 mesh, mobile phase CH2Cl2/MeOH 90:9). The corresponding fractions were combined and evaporated to afford a slightly yellow foam which was dissolved in MeOH and treated with ethereal HCl to yield 520 mg (65%) of the compound 10 as colorless crystals. For analyses a small sample was recrystallized from MeOH. M.p. >250°C (dec). IR (KBr):3515 and 3220 CNH, NH, OH)cm'\ CI-
MS: m/z 443 (M*+l). ^-NMR (DMSO-d6): δ 11.30, 9.12, 8.93 (3 s/NH, NH, OH), 7.34 (m, 2 arom. H), 7.09 (t, J=8.3 Hz, 1 arom. H), 6.95 (t, J=8.3 HZ, 1 arom. H), 6.63 (d, J=8.1 Hz, 1 arom. H), 6.56 (d, J=8.1 Hz, 1 arom. H), 3.24 (s, OCH3), 1.87 (s, CH3-
C(5)). Analysis calculated for C2gH30N2O3. HCl. 0.7 H20 (491.67):C 68.41, H 6.64, N 5.70, Cl 7.21; found: C 68.52, H 6.86, N 5.65, Cl 7.48.
Example 7
Synthesis of 17-Allyl-6,7-dehydro-4,5α-epoxy-3-hydroxy-5-methyl-14-n- propyloxy-6,7-2',3'-indolomorphinan. CH3S03H (compound 15).
A mixture of 7,8-dihydro-5-methyl-14-n-propyloxycodeinone described in our copending application with priority from May 18, 1994) (9; 2.67 g, 7.19 mmol),
KHC03 (3.6 g, 35.93 mmol), 1-chloroethyl chloroformate (4.73 ml, 43.12 mmol), and 35 ml of 1,2-dichloroethane was stirred under reflux for 3.5 h. After cooling, the inorganic material was filtered off and the filtrate evaporated. The residue (4.67 g of a yellowish oil of 17-(l-chloroethoxy)- carbonyl-4,5α-epoxy-3-methoxy- 5-methyl-14-n-propyloxymorphinan-6-one (compound 11); pure by TLC) was not further purified and characterized. A solution of the compound 11 in MeOH was refluxed for 1 h and then evaporated. The residue (3.54 g slightly brown foam) was crystallized from 2.5 ml MeOH/2 ml diethyl ether to give 1.68 g (66%) of
4,5α-epoxy-3-methoxy-5-methyl-14-n-propyloxy-morphinan-6-one hydrochloride
(compound 12). M.p. 186-188°C. IR (KBr): 3425 CNH2), 1725 (CO)cm'\ EI-MS: m/z
357 (Ml. !H-NMR (DMSO-d6): σ 10.11 and 8.15 (2 broad s, *NH2), 6.83 (d, J=8.2
Hz, 1 arom. H), 6.74 (d, J=8.2 Hz, 1 arom. H), 3.78 (s, CH30), 1.48 (s, CH3-C(5)),
0.95 (t, J=7.4 Hz, CHg). Analysis calculated for C21H27N04. HCl. 0.6 MeOH
(413.14): C 62.80, H 7.42, N 3.39, Cl 8.58; found: C 62.66, H 7.34, N 3.40, Cl 8.98. A mixture of the compound 12 (1.45 g, 3.68 mmol), allyl bromide (0.36 ml, 4.06 mmol), potassium carbonate (2.9 g, 20.8 mmol), and 10 ml of anhydrous N,N- dimethyl formamide was stirred at 80°C (bath temperature) for 1.5 h. The inorganic solid was filtered off and the filtrate evaporated to give 1.7 g of a yellowish oily residue. This residue was partitioned between CH2C12 and H20.
The organic layer was washed with HjO and brine, dried over Na2S04 and evaporated. The residue (1.375 g of a slightly yellow oil) was crystallized from
ethanol to yield 1.28 g (88%) of 17-allyl-4,5α-epoxy-3-methoxy-5-methyl-14-n- propyloxymorphinan-6-one (compound 13) as slightly yellow crystals. M.p. 122-
124°C. IR(KBr): 1720 (CO)cm'\ EI-MS: m/z 397 (M*). ^-NMR (CDC13): δ 6.63 (d,
J=8.3 Hz, 1 arom. H), 6.55 (d, J=8.3 Hz, 1 arom. H), 5.79 (m, 1 olef. H), 5.13 (m, 2 olef. H), 3.84 (s, OCH3), 1.60 (s, CH3-C(5)), 1.00 (t, J=7.4 Hz, CH3). Analysis
calculated for C24H3]N04 (397.51): C 72.52, H 7.86, N 3.52; found: C 72.14, H 7.76,
N 3.44. A I M solution of boron tribromide in CH2C12 (10.8 ml) was added to an
ice-cooled solution of the compound 13 (577 mg, 1.45 mmol) in 75 ml of CH2C12 at
once. After stirring at 0-5°C for 2 h, a mixture of 20 g ice and 4 ml of cone NH4OH was added. The resulting mixture was stirred at room temperature for 30 min and the extracted with CH-X.^ (3x50 ml). The combined organic layers were washed
with brine (70 ml), dried over Na2S04 and evaporated. The residue (600 mg brownish foam) was converted into the hydrobromide salt in the usual way and crystallized from MeOH to afford 314 mg (47%) of 17-allyl-4,5α-epoxy-3-hydroxy- 5-memyl-14-n-propyloxymo hinan-6-one hydrobromide (compound 14). M.p. 244-247°C (dec). IR (KBr): 3441 and 3332 CNH, OH), 6.68 (d, J=8.2 Hz, 1 arom. H),
6.62 (d, J=8.2 Hz, 1 arom. H), 5.92 (m, 1 olef. H), 5.67 (m,2 olef. H), 1.49 (s, CH3-
C(5)), 0.96 (t, J=7.2 Hz, CH3).
A mixture of the compound 14 (300 mg, 0.65 mmol), phenylhydrazine hydrochloride (187 mg, 1.29 mmol), and 30 ml of glacial acetic acid was refluxed for 7.5 h. After cooling, the reaction mixture was poured on ice, alkalized with cone NH4OH and extracted with C ^ l^ (3x60 ml). The combined organic layers
were washed with H20 (3x80 ml) and brine (50 ml), dried over Na2S04 and evaporated. The residue (325 mg brownish foam) was converted into the methane sulfonate in the usual way and recrystallized from MeOH/diethyl ether to yield
264 mg (74%) of the title compound 15. Recrystallization of a small portion of this material from ethanol afforded an analytical sample. M.p. >256°C. FAB-MS: m/z
457 (M*+l), ^-NMR (DMSO-d6): δ 11.29, 9.17 and 8.45 (3 s, *NH, NH, OH), 7.32
(d, J=8.2 Hz, 2 arom. H), 7.10 (t, J=8.2 Hz, 1 arom. H), 6.94 (t, J=8.2 Hz, 1 arom. H),
I 6.59 (s, 2 arom. H), 5.90 (m, 1 olef. H), 5.68 (m, 2 olef. H), 1.88 (s, CH3-C(5)), 0,55 (t,
J=7.3 Hz, CH3). Analysis calculated for C29H32N203H. 0.5 H20 (561.70): C 64.15, H 66.4, N 4.99, S 5.72; found: C 64.08, H 6.87, N 5.09, S 5.87.
Example 8
Synthesis of 17-(Cy clopropylmethyl)-6,7-dehy dro-4,5α-epoxy-3-hydroxy-5- methyl-14-n-propyloxy-6,7-2,3'-indolomorphinan. CH3S03H (compound 18).
A mixture of 4,5α-epoxy-3-methoxy-5-methyl-14-n-propyloxymorphinan-6-one hydrochloride (compound 12 of Example 7) (1.46 g, 3.71 mmol), potassium carbonate (2.24 g, 16.24 mmol), cyclopropylmethyl chloride (0.43 ml, 4.44 mmol), and 15 ml of anhydrous N,N-dimethyl formamide was stirred at 85°C (bath temperature) for 36 h. The inorganic solid was filtered off and the filtrate evaporated. A solution of the residue in 30 ml of CPL-C^ was washed with HzO
(3x30 ml), dried over Na2S04 and evaporated. The residue (1,69 g orange-yellow oil) was dissolved in diethyl ether and treated with ethereal HCl to give 920 mg (55%) of 17-(cyclopropylmethyl)-4,5α-epoxy-3-methoxy-5-methyl-14-n- propyloxymorphinan-6-one hydrochloride (compound 16) as colorless powder.
M.p. 156-158°C. IR (KBr): 3400 CNH), 1723 (CO) cm'1. CI-MS: m/z 412 (M*+l). αH-
NMR (DMSO-d6): δ 8.57 (s, *NH), 6,85 (d, J=8.2 Hz, 1 arom. H), 6.75 (d, J=8.2 Hz, 1
arom. H), 3.79 (s, OCH3), 1.51 (s, CH3-C(5)), 0.97 (t, J=7.4 Hz, CH3). Analysis
calculated for C25H33N04. HCl. 0.6 H20 (458.81): C 65.45, H 7.73, N 3.05, Cl 7.73; found: C 65.45, H 7.85, N 3.08, Cl 7.84.
A I M solution of boron tribromide in CH2C12 (7.3 ml) was added at once to an
ice-cooled solution of the compound 16 (480 mg, 0.97 mmol) in 50 ml of CH2C12.
After 50 min stirring at 0-5°C, a mixture of 13 g ice and 3 ml cone NH4OH was added. The resulting mixture was stirred at room temperature for 30 min and the extracted with CH2C12 (3x30 ml). The combined organic layers were washed with
brine (45 ml), dried over Na2S04 and evaporated. The residue (204 mg slightly brown foam) was treated with 0.5 ml hot MeOH to afford 302 mg (55 %) of 17- (cyclopropylmethyl)-4,5α-epoxy-3-hydroxy-5-me yl-14-n-propyloxymorphinan-
6-one (compound 17). M.p. 184-186°C. IR (KBr): 3390 (OH), 1720 (CO)cm '\ CI-MS:
m/z 397 (M*+l). JH-NMR (CDC13): δlθ.24 (broad s, OH), 6.73 (d, J=8.2 Hz, 1 arom.
H), 6.65 (d, J=8.2 Hz, 1 arom. H)1.62 (s, CH3-C(5)), 1.00 (t,J=7.3 Hz, CH3). Analysis
calculated for C24H31N04. 0.6 MeOH (416.74): C 70.90, H 8.08, N 3.36; found: C 70.76, H 7.73, N 3.52.
A mixture of compound 17 (230 mg, 0.58 mmol), phenylhydrazine hydrochloride (142 mg, 0.98 mmol), and 23 ml of glacial acetic acid was refluxed for 3.5 h. After cooling, the reaction mixture was poured on ice, alkalized with con. NH4OH and
extracted with CH2C12 (3x40 ml). The combined organic layers were washed with
H202x50 ml) and brine (50 ml), dried and evaporated. The residue (262 mg yellow-brown foam) was converted in the usual way into the methane sulfonate and crystallized from MeOH/diethyl ether to yield 204 mg (62%) of the compound 18. M.p. 295-298 (dec.) FAB-MS: m/z 471 (M*+l). ^-NMR (DMSO-d6) δ 11.27, 9.12 and 8.46 (3s, *NH, NH, OH), 7.14 (m, 4 arom. H), 6.59 (s, 2 arom. H),
1.90 (s, CH3-C(5)), 0.67 (t, J=7.3 Hz, CH3) Analysis calculated for C3JtiMN2Oy
CH3S03H. 1.5 H20 (584.74): C 62.71, H 6.96, N 4.72, S 5.40; found: C 62.67, H 6.96, N 4.79, S 5.40.
Examples 9-24, and 28-30 illustrate further compounds, which can be prepared according to one of the methods described above.
Example 9
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-hydroxy-3-
(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 19).
M.p.l29-130°C. 1H-NMR (CDC13): δ 7.45 (d, J = 8.3 Hz, 1 arom. H), 7,37 (d, J = 8.3
Hz, 1 arom. H), 7.25 (m, 1 arom. H), 7.16 (m, 1 arom.), 6.86 (d, J = 8.3 Hz, 1 arom. H), 6.60 (d, J = 8.3 Hz, 1 arom. H), 5.63 (s, H-C(5)), 5.17 and 5.06 (2 d, J = 6.6, 6.6
Hz, 0CH20), 3.42 (s, CH30).
Example 10
17-Cyclopropylmethyl-6,7-dehydro-4^α-epoxy-14-hydroxy-3-(methoxymethoxy)- 6,7-2' ,3'-(N-methoxymethylindolo)morphinan (compound 20).
U NMR (CDC13): δ 7.44 (m, 2 arom. H), 7.20 (m, 1 arom. H), 7.07 (m, 1 arom. H), 6.82 (d,J = 8 Hz, 1 arom. H), 6.58 (J = 8 Hz), 5.81 (s, H-C(5)), 5.79 and 5.50 (2 d, J = 10.8, 10.8 Hz, NCH.O), 5.12 and 5.50 (2 d, J = 6.4, 6.4 Hz, OCK.O), 3,41 and 3.33 (2
s, 2 CH30).
Example 11
17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5α-epoxy-14- 3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 21).
M.p. 180-182 °C. IH NMR (CDC13): δ 7.41 (d, J = 8.3 Hz, 1 arom. H), 7.33 (d, J = 8.3
Hz, 1 arom. H), 7.23 (m, 1 arom. H) 7.14 (m, 2 arom. H), 7.03 and 7.01 (2 d, J = 7.3, 7.3 Hz), 6.84 (d, J, 8.3 Hz, 1 arom. H) 6.59 (d, J = 8.3 Hz, 1 arom. H), 5.56 (s, H-
C(5)), 5.32 and 4.68 (2 d, J = 8.7, 8.7 Hz, OC^Ar), 5.16 and 5.05 (2 d, J = 6.6, 6.6
Hz, OCH20), 3.41 (s, CH30).
Example 12
17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5α-epoxy-3- hydroxy-6,7-2',3'-benzo[b]furanomorphinan (compound 22).
M.p. 193-195 °C (dec). IH NMR (CDC13): δ 7.42 (d, J = 8.3 Hz, 1 arom. H), 7.33 (d, J
= 8 Hz, 1 arom. H), 7.24 (m, 1 arom. H) 7.14 (m, 2 arom. H), 7.03 and 7.01 (2 d, J = 7.3 Hz, 1 arom. H), 6.64 (d, J, 8.1 Hz, 1 arom. H) 6.56 (d, J = 8.1 Hz, 1 arom. H), 5.58 (s, H-C(5)), 5.32 and 4.68 (2 d, J = 8.6 Hz, OCH2 Ar).
Example 13
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-(methoxymethoxy)-14-(3'- nitrobenzyloxy)-6,7-2'^3'-benzo[b]furanomorphinan (compound 23).
'H NMR (CDC13): δ 8.25 (s, 1 arom. H), 7.28 (m, 4 arom. H), 7.15 (m, 1 arom. H) 6.87 (d, J = 8.3 Hz, 1 arom. H), 6.62 (d, J = 8.3 Hz, 1 arom. H), 5.66 (s, H-C(5)), 5.17
and 5.07 (2 d, J =6.6 Hz, OCH20) 4.92 and 4.44 (2 d, J = 11.5 Hz, OCH2Ar), 3.42 (s,
CH30).
Example 14
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-(3'- nitrobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride (compound 24).
M.p. > 230 °C (dec). IH NMR (DMCO-d6): δ 9.40 (s, OH), 9.15 (broad s, +NH), 7.84
(s, 1 arom. H) 7.60 (d, J = 8.8 Hz, 1 arom. H), 7.53 (d, J = 7.6 Hz, 1 arom. H), 7.45 (d, J = 8 Hz, 1 arom. H) 7.23 (d, J = 7.6 Hz, 1 arom. H), 7.19 (d, J = 7.6 Hz, 1 arom. H), 6.98 (m, 1 arom. H) 6.88 (d, J = 7.6 Hz, 1 arom. H) 6.69 (d, J =8.3 Hz, 1 arom. H), 6.66 (d, J = 8.3 Hz, 1 arom. H), 6.03 (s, H-C(5)), 4.98 and 4.87 (2 d, J = 14, 14 Hz, OCH2Ph).
Example 15
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-(methoxymethoxy)-14-(2- naphtylmethoxy)-6,7-2'-3'-benzo[b]furanmorphinan (compound 25).
M.p. 198-201 °C. IH NMR (CDC13): δ 7.72-7.08 (m, 11 arom. H), 6.86 (d, J = 8.3 Hz, 1 arom. H), 6.62 (d, J = 8.3 Hz, 1 arom. H), 5.68 (s, H-C(5)), 5.17 and 5.07 (2 d, J = 6.6, 6.6 Hz, OCH20), 5.01 and 4.57 (2 d, J = 11.2, 11.2 Hz, OCH2Ar), 3,42 (s, CH30).
Example 16
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-(2'- naphtylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride (compound 26).
M.p. > 215 °C. IH NMR (DMSO-d6): δ 9.42 (s, OH), 9.00 (broad s, +NH), 7.68-6.85 (m, 11 arom. H), 6.71 (d, J = 8 Hz, 1 arom. H), 6.67 (d, J = 8 Hz, 1 arom. H), 6.04 (s, H-C(5)), 4.92 (s, OCH2Ar).
Example 17
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-(2'-fluorobenzyloxy)-3- (methoxymethoxy)-6,7-2'-3'-benzo[b]furanmorphinan (compound 27).
αH NMR (DMSO-d6): δ 7.56 (d, J = 8 FIz, 1 arom. H), 7.49 (d, J = 8 Hz, 1 arom. H), 7.31 (m, 1 arom. H), 7.21 (m, 1 arom . H), 6.81 (d, J = 8.4 Hz, 1 arom. H), 6.67 (d, J = 8.4 Hz), 5.72 (s, H-C(5)), 5.06 and 5.01 (2 d, J = 6.4, 6.4 Hz, OCH20), 4.89 and
4.57 (2 d, J = 11.6, 11.6 Hz, OCR, Ar), 3,33 (s, CH30).
Example 18
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-(2'-fluoro-benzyloxy)-3- hydroxy-6,7-2',3'-benzo[b]furanomorphinan Hydrochloride (compound 28).
M.p. > 215 °C. IH NMR (CDC13): δ 9.45 (s, OH), 9.04 (broad s, +NH), 7.54 (d, J = 8.4 Hz, 1 arom. H) 7.31-6.73 (m, 7 arom. H), 6.71 (d, J = 8.2 Hz, 1 arom. H), 6.66 (d, J = 8.2 Hz, 1 arom. H), 5.98 (s, H-C(5)), 4.81 and 4.84 (2 d, J = 12 Hz, OCH2 Ar).
Example 19
14-Cinnamyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3- (methoxymethoxy)-6,7-2'-3'-benzo[b]furanomoφhinan (compound 29).
M.p. 156-159 °C. IH NMR (CDC13): δ 7.47 (d, J = 8 Hz, 1 arom. H), 7.33 (d, J = 8
Hz, 1 arom. H), 7.28-7.07 (m, 7 arom. H), 6.84 (d, J = 8.4 Hz, 1 arom. H), 6.59 (d, J = 8.4 Hz, 1 arom . H), 6.38 (d, J = 16 Hz, 1 olef. H), 6.13 (m, 1 olef. H), 5.68 (s, H-
C(5)), 5.16 and 5.06 (2 d, J = 6.4, 6.4 Hz, OCH20), 4.46 and 4.11 (2 m,OCH2Ar), 3,42
(s, CH30).
Example 20
14-Cinnamyloxy-17-cyclopropylmethyl-6,7-dehydro-4,5α-epoxy-3-hydroxy-6,7-2'- 3'-benzo[b]furanomorphinan Salicylate (compound 30).
l NMR (CDC13): δ 7.94 (d, J = 8 Hz, 1 arom. H), 7.35 (d, J = 8 Hz, 1 arom. H), 7.30-6.73 (m, 12 arom. H), 6.56 (d, J = 8 Hz, 1 arom. H), 5.96 (s, 2 olef. H), 5.55 (s, H-C(5)), 4.33-4.02 ( m, OCH,Ar).
Example 21
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-methoxy-3- (me oxymemoxy)-6,7-2'-3'-benzo[b]iαιranomoφhinan (compound 31).
'H NMR (DMSO-d6): δ 7.7.56 (d, J = 8 Hz, 1 arom. H), 7.52 (d, J = 8 Hz, 1 arom. H), 7.32 (dd, J = 8, 8 Hz, 1 arom. H), 5.64 (s, H-C(5)), 5.05 and 5.00 (2 d, J = 6.4, 6.4 Hz, OCH20), 3.32 (CH30).
Example 22
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-methoxy-6,7-2'-3'- benzo[b]furanomorphinan hydrochloride (compound 32).
M.p. > 240 °C. 'H NMR (DMSO-d6): δ 9.47 (s, OH), 9.17 (broad s, +NH), 7.61 (d, J
= 8 Hz, 1 arom. H), 7.53 (d, J = 8 Hz, 1 arom. H), 7.36 (dd, J = 8, 8 Hz, 1 arom. H), 7.27 (dd, J = 8, 8 Hz, 1 arom. H), 6.72 (d, J = 8.4 Hz, 1 arom. H), 6.65 (d, J = 8.4 Hz,
1 arom. H), 5.90 (s, H-C(5)), 3.35 (s, CH30).
Example 23
17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5α-epoxy-3- (methoxymethoxy)-6,7-2'-3'-(N-methoxymethylindolo)morphinan (compound 33).
:H NMR (CDClg): δ 7.56 (m, 1 arom. H), 7.44 (m, 1 arom. H), 7.37-7.17 (m, 3 arom .
H), 7.01 (m, 1 arom. H), 6.91 (m, 1 arom. H), 6.83 (d, J = 8.2 Hz, 1 arom. H), 6.59 (dd, J = 8.2, 8.2 Hz, 1 arom. H), 5.90 (s, H-C(5)), 5.82 and 5.55 (2 d, J = 11.2, 11.2
Hz, NCH20), 5.13 and 5.03 (2 d, J = 6.4, 6.4 Hz, OCH ), 4.98 and 4.56 (2 d, J = 13,
13 Hz, OCH2Ar), 3.40 and 3.26 (2 s, 2 CH30).
Example 24
17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5α-epoxy-3- hydroxy-6,7-2'-3'-indolomorphinan hydrochloride (compound 34).
M.p. > 250 °C (dec). IH NMR (DMSO-d6): δ 11.38 (s, NH), 9.38 (s, OH), 8.76 (broad s, +NH), 7.34-6.85 (m, 8 arom. H), 6.72 (d, J = 8 Hz, 1 arom. H), 6.64 (d, J
8 Hz, 1 arom. H), 5.93 (s, H-C(5)), 4.80 and 4.67 (2 d, J = 13, 13 Hz, OCH2 Ar).
Example 25
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-3,14-dimethoxy-4,5α-epoxy-6,7- 2'-3'-benzo[b]furanomorphinan (compound 35).
Sodium hydride (144 mg, 6 mmol; obtained from 240 mg of 60% sodium hydride dispersion in oil by washings with n-hexane) was added to a solution of naltriben methanesulfonate (P.S. Portoguese et al., J. Med. Chem., Vol. 34: 1715-1720, 1991) 500 mg, 0.97 mmol) in 10 ml of anhydrous N,N-dimethyl-formamide at 0 °C. The resulting mixture was stirred at 0 °C for 15 min and then at room temperature for another 30 min. After cooling to 0 °C, dimethyl sulfate (380 μl, 4 mmol) was added and stirring was continued at first at 0 °C for 30 min and then at room temperature for 3 h. Excess sodium hydride was destroyed by addition of MeOH and H-,0. The resulting mixture was extracted with ethyl acetate (3 x 40 ml), the
combined organic layers were washed with H20 (2 x 30 ml) and brine (2 x 30 ml),
dried over Na2S04 and evaporated to give a crystalline residue which was recrystallized from MeOH to afford 320 mg (74 %) of compound 35. M.p. 221-224 °C (dec). IH NMR (CDC13): δ 7.47-7.14 (m, 4 arom. H), 6.64 (d, J =8.4 Hz, 1 arom.
H), 6.59 (d, J = 8.4 Hz, 1 arom . H), 5.62 (s, H-C(5)), 3.78 (s, CH30-C(3)), 3.31 (s,
CH30-C(14)).
Example 26
Synthesis of 17-Cyclopropylmethyl-6,7-dehydro-4,5α-epoxy-14-hydroxy-6,7-2',3'- benzo[b]furanomorphinan (compound 36).
A mixture of 3-deoxyonaltrexone (R. Krassnig and H. Schmidhammer, Heterocycles, Vol. 38: 877-881, 1994) (1,3 g, 3.99 mmol), O-phenylhydroxylamine hydrochloride (750 mg, 5.15 mmol), methanesulfonic acid (0.75 ml, 11.55 mmol), and ethanol (30 ml) was refluxed for 20 h. After cooling, the mixture was diluted with H20, alkalized with cone. NH4OH and extracted with CH2C12 (4 x 40 ml).
The combined organic layers were washed with Hβ (2 x 30 ml) and brine (30 ml),
dried over Na2S04 and evaporated to give a brownish oil which was crystallized
form MeOH to yield 1.1 mg (69 %) of compound 36. M.p. > 260 °C. *H NMR
(CDC13): δ 7.45 (d, J = 8 Hz, 1 arom. H), 7.37 (d, J = 8 Hz, 1 arom. H), 7.26-7.13 (m,
2 arom. H), 7.01 (dd, J = 7.8, 7.8 Hz, 1 arom. H), 6.67 (d, J = 7.8 Hz, 1 arom. H), 6.59 (d, J = 7.8 Hz, 1 arom. H), 5.59 (s, H-C(5)), 5.00 (broad s, OH).
Example 27
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-14-hydroxy-6,7-2'- 3'-indolomorphinan hydrochloride (compound 37).
A mixture of 3-deoxyonaltτexone (R. Krassnig and H. Schmidhammer, Heterocycles, Vol. 38: 877-881, 1994) (1,5 g, 4.6 mmol), phenylhydrazine hydrochloride (1.0 mg, 6.9 mmol), 1M HCl in ether (5 ml), and methanol (20 ml)
was stirred at room temperature for 3 days. After concentration to ca. half of the original volume in vacuo, the solution was refrigerated overnight. The colorless crystals formed were collcted to yield 1.54 g (77 %) of compound 37. M.p. > 240 °C
(dec). IH NMR (DMSO-d6): δ 11.37 (s, NH), 9.01 (broad s, +NH), 7.36-6.94 (m, 5 arom. H), 6.78 (d, J = 7.8 Hz, 1 arom. H), 6.59 (d, J = 7.8 Hz, 1 arom. H), 6.55 (s, OH).
Example 28
17(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-(3'- chlorobenzyloxy)-6,7,2',3'-benzo[b]furanomoφhinan, hydrochloride (compound 39).
]H NMR (DMSO-d6): δ 9.40 (s, OH), 8.59 (broad s, +NH), 7.53-6.90 (m, 8 arom. H),
6.65 (s, 2 arom. H), 6.03 (s, H-C(5)), 4.74 and 4.62 (2 d, J=13.6, 13.6 Hz, OCH2(3'-
ClPh)). Analysis calculated for C33H30ClNO4. HCl. 1.5 H20: C 65.67, H 5.68, N 2.32; found: C 65.31, H 5.37, N 2.33.
Example 29
17-(Cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy-14-(2'- chlorobenzyloxy)-6,7,2'^'-benzo [b]f ur anomorphinan Hydrochloride (compound 41).
M.p. > 220°C. *H NMR (DMSO-d6): δ 9.40 (s, OH), 8.59 (broad s, +NH), 7.56-6.90
(m, 8 arom. H), 6.66 (m, 2 arom. H), 6.03 (s, H-C(5)), 4.74 (s, OCH2(2-ClPh)).
Analysis calculated for C33H30ClNO4. Hcl. 1.5 JD: C 65.67, H 5.68, N, 2.32. Found: C 65.72, H 5.48, N 2.25.
Example 30
14-Allyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-hydroxy- -allyl- 6,7-2',3'-indolomorphinan hydrochloride (compound 42).
NMR of the free base (colorless oil) αH NMR (CDClg): δ 7.40 (d, J = 8.4 Hz, 1 arom. H), 7.24 (m, 1 arom. H), 7.15 (m, 1 arom. H), 7.03 (m, 1 arom. H), 6.57 (d, J = 8.4 Hz, 1 arom. H), 6.50 (d, J = 8.4 Hz, 1 arom. H), 6.08 (m, 1 olef. H), 5.76 (m, 1 olef. H), 5.72 (s, H-C(5)), 5.15-4.75 (m, 6 H, CH2N,2 CH2 = C), 4.24 and 3.92 (2 dd, J = 12.4, 4.8 Hz, CH20).
This free base was dissolved in ethyl ether and treated with HCl /ether solution HCl at 0°C. Isolation of the precipitate provided the title compound 42 as a solid.
Pharmaceutical preparations
For the preparation of a pharmaceutical formulation, the active ingredient may be formulated to an injection, capsule, tablet, suppository, solution or the like. Oral formulation and injection are preferably employed. The pharmaceutical formulation may comprise the δ-selective antagonist alone or may also comprise expedients such as stabilizers, buffering agents, diluents, isotonic agents, antiseptics and the like. The pharmaceutical formulation may contain the above described active ingredient in the amount of 1-95 % by weight, preferably 10-60 % by weight. The dose of the active ingredient may be appropriately selected depending on the objects of administration, administration route and conditions of the patients. The active ingredient may be administered in doses between 1 mg and 1 g per day in case of administration by injection and in doses between 10 mg and 5 g per day in case of oral administration. The preferred dose for injection is 20-500 mg per day.
Biological studies
δ- Antagonism was assessed using the electrical stimulated guinea-pig ileum longitudinal muscle preparation (GPI; containing μ and K opioid receptors) and mouse vas deferens preparation (MVD; containing μ, K and δ opioid receptors) (H. Schmidhammer et al., J. Med. Chem., Vol. 32: 418-421, 1989; H Schmidhammer et al., J. Med. Chem., Vol. 33: 1200-1206, 1990). The activity of the compound 1 of the Examples for inhibiting the suppression of contraction of the organs by three receptor selective agonists (DAMGO, μ; Cl 977, iς DPDPE, δ) was measured. The compound exhibited δ-selective opioid antagonism with very good μ/δ and κ/δ selectivity ratios.
Conclusion
The pharmacological studies of the novel morphinan derivatives of formula (I) of the present invention have shown that these compounds have selectivity for δ opioid receptors and are effective as opioid antagonists.